Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer

Thanh H. Dellinger, Ernest S. Han, Mustafa Raoof, Byrne Lee, Xiwei Wu, Hyejin Cho, Ting Fang He, Peter Lee, Marianne Razavi, Winnie S. Liang, Daniel Schmolze, Saul J. Priceman, Stephen Lee, Wei Chien Lin, Jeff F. Lin, Mehdi Kebria, Amy Hakim, Nora Ruel, Daphne B. Stewart, Edward W. WangBenjamin I. Paz, Mark T. Wakabayashi, Mihaela C. Cristea, Lorna Rodriguez-Rodriguez

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


PURPOSEHyperthermic intraperitoneal chemotherapy (HIPEC) confers a survival benefit in epithelial ovarian cancer (EOC) and in preclinical models. However, the molecular changes induced by HIPEC have not been corroborated in humans.PATIENTS AND METHODSA feasibility trial evaluated clinical and safety outcomes of HIPEC with cisplatin during optimal cytoreductive surgery (CRS) in patients with EOC diagnosed with stage III, IV, or recurrent EOC. Pre- and post-HIPEC biopsies were comprehensively profiled with genomic and transcriptomic sequencing to identify mutational and RNAseq signatures correlating with response; the tumor microenvironment was profiled to identify potential immune biomarkers; and transcriptional signatures of tumors and normal samples before and after HIPEC were compared to investigate HIPEC-induced acute transcriptional changes.RESULTSThirty-five patients had HIPEC at the time of optimal CRS; all patients had optimal CRS. The median progression-free survival (PFS) was 24.7 months for primary patients and 22.4 for recurrent patients. There were no grade 4 or 5 adverse events. Anemia was the most common grade 3 adverse event (43%). Hierarchical cluster analyses identified distinct transcriptomic signatures of good versus poor responders to HIPEC correlating with a PFS of 29.9 versus 7.3 months, respectively. Among good responders, significant HIPEC-induced molecular changes included immune pathway upregulation and DNA repair pathway downregulation. Within cancer islands, % programmed cell death protein 1 expression in CD8+ T cells significantly increased after HIPEC. An exceptional responder (PFS 58 months) demonstrated the highest programmed cell death protein 1 increase. Heat shock proteins comprised the top differentially upregulated genes in HIPEC-treated tumors.CONCLUSIONDistinct transcriptomic signatures identify responders to HIPEC, and preclinical model findings are confirmed for the first time in a human cohort.

Original languageEnglish (US)
Article numbere2100239
JournalJCO Precision Oncology
StatePublished - Mar 1 2022

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer'. Together they form a unique fingerprint.

Cite this